Shanghai MicroPort Endovascular MedTech Co., Ltd. provided earnings guidance for the six months ended 30 June 2024. For the six months ended 30 June 2024, the revenue of EV MedTech is expected to be between RMB 777.0281 million and RMB 808.1092 million, representing an increase of between approximately 25% and 30% as compared with the same period last year. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB 391.3368 million and RMB 419.2894 million, representing an increase of between approximately 40% and 50% as compared with the same period last year.

The increases in revenue and profit were mainly attributable to the continuous growth of the innovative products of EV MedTech, including Castor Branched Aortic Stent Graft and Delivery System, Minos Abdominal Aortic Stent Graft and Delivery System and Reewarm PTX Drug Balloon Dilatation Catheter, and the rapid growth in the numbers of hospitals entered and terminal implants for the new products of EV MedTech, including Talos Thoracic Stent Graft System and the Fontus Branched Surgical Stent Graft System, which contributed to the steady growth in the sales revenue and profit of EV MedTech and further enhanced its competitiveness in the aortic and peripheral vascular intervention markets, achieving a rapid period-on-period increase in the overall sales volume of EV MedTech in the first half of the year, which resulted in a rapid period-on-period growth in net profit.